Indication DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).As an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

CRSwNP, driven primarily by Type 2
inflammation, affects patients’
quality of life

Patients with CRSwNP experience a high symptom burden and reduced quality of life (QoL)1,2

NASAL SYMPTOMS

  • Congestion
  • Sneezing
  • Decreased sense
    of smell/taste
  • Runny nose
  • Nasal discharge
  • Cough

EAR AND FACIAL SYMPTOMS

  • Facial pain
  • Facial pressure
  • Ear pain
  • Ear fullness
  • Dizziness

QoL

  • Difficulty falling/
    staying asleep
  • Fatigue
  • Waking up tired
  • Reduced concentration
  • Reduced productivity

PSYCHOLOGICAL

  • Frustrated, restless,
    irritable
  • Sad
  • Embarrassed

CRSwNP can remain uncontrolled in patients on standard-of-care therapies, which can lead to multiple sino-nasal surgeries and cycles of oral corticosteroid use1,3,4

UP TO 80 %

of patients enrolled in DUPIXENT trials had a history of prior SCS use1

UP TO 72 %

of patients enrolled in DUPIXENT clinical trials had a history of ≥1 prior surgery1

DUPIXENT TARGETS UPPER AND LOWER AIRWAY INFLAMMATION IN CRSwNP AND ASTHMA

DUPIXENT is the first and only dual inhibitor of IL-4 and IL-13 signaling, two cytokines that contribute to underlying Type 2 inflammation in CRSwNP1,5,a

CRSwNP is predominantly characterized by Type 2 inflammation of the nose and paranasal sinuses and is frequently associated with comorbidities of the lower airway4-7

Upper airway
CRSwNP Lower airway
Asthma

Mast cell
IL-4
Eosinophil
IL-13
B cell
Th2 cell
IgE release
  • aThe mechanism of dupilumab action in asthma has not been established.

DUPIXENT is indicated as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

  • CRSwNP, chronic rhinosinusitis with nasal polyposis; SCS, systemic corticosteroid.
SEE THE FULL STUDY DESIGN SEE THE Safety data

Identify CRSwNP
patients appropriate
for DUPIXENT

View Patients
Dosing & Administration
VIEW DOSING
Contact a Rep
LEARN MORE ABOUT DUPIXENT
DUPIXENT MyWay®
ACCESS PATIENT RESOURCES

References:

  1. DUPIXENT Prescribing Information.
  2. Abdalla S, Alreefy H, Hopkins C. Prevalence of sinonasal outcome test (SNOT-22) symptoms in patients undergoing surgery for chronic rhinosinusitis in the England and Wales National prospective audit. Clin Otolaryngol. 2012;37(4):276-282.
  3. DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550-555.
  4. Stevens WW, Peters AT, Hirsch AG, et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2017;5(4):1061-1070.e3.
  5. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
  6. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45-53.
  7. Gelardi M, Ianuzzi L, Tafuri S, Passalacqua G, Quaranta N. Allergic and non-allergic rhinitis: relationship with nasal polyposis, asthma and family history. Acta Otorhinolaryngol Ital. 2014;34(1):36-41.